NCT07420023
The Satiety Control Optimization by Nutritional Enhancement Study
Recruiting · Not Applicable · University College Cork · registry updated 2026-02-19
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
High-glycaemic foods contribute to elevated risk of obesity, type 2 diabetes, and cardiometabolic disease. Replacing digestible carbohydrates with dietary fibres is known to reduce postprandial glycaemic excursions, enhance satiety, and support beneficial microbial fermentation. However, limited evidence exists on how interactions between different isolated fibres within a processed food matrix may modulate these responses, particularly when such interactions could recreate structural features of intrinsic plant fibre networks that naturally restrict starch accessibility and alter fermentation dynamics. This randomized, single-blinded, placebo-controlled crossover trial will investigate how isolated dietary fibres, alone and in combination, influence metabolic and microbial responses when incorporated into a commonly consumed cereal-based food (scone). Overweight but otherwise healthy adults (BMI 25-\<30 kg/m²) will consume seven fibre-enriched scone formulations across two consecutive mornings per intervention phase....
Inclusion
- Be willing and able to give written informed consent.
- Be between 18 and 45 years of age.
- Have a BMI of =25\<30kg/m2(overweight).
- Have a waist circumference of \>94cm for a male, \>80cm for a female (increased risk of metabolic syndrome).
- Have had a stable body weight (\<5% change over the past three months).
- Be in general good health as determined by the investigator through interview and vital signs (blood pressure, pulse, temperature). Systolic blood pressure less than 160mm Hg and diastolic blood pressure less than 100 mm Hg (defined as Hypertension stage 2).
Exclusion
- Pregnant, lactating, or post-menopausal women, or women who are planning to become pregnant over the study period.
- Have had antibiotic treatment within three months before baseline.
- Are taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of study results; to include anti-inflammatory drugs, H2 blockers, antacids, proton pump inhibitors, anti-hypertensive medications, corticosteroids, laxatives, enemas, antibiotics, anti-coagulants, and immunosuppressant medication. Participants should have a wash-out period of at least two weeks for each of these medications except for antibiotics, which should not have been taken in the previous three months. Participants taking proton pump inhibitors and medications for chronic conditions (e.g., anti-hypertensive medication) will be allowed into the study if the dose has been stable for at least two months before the study baseline visit.
- Have a history or indication of drug and/or alcohol abuse at the time of enrolment.
- Have a habitual alcohol consumption of \>2 alcoholic beverages/day (\>28g ethanol daily).
- Follow a vegetarian or vegan diet.